Doxorubicin Hydrochloride Liposome Injection
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ovarian Epithelial Cancer Recurrent
Conditions
Ovarian Epithelial Cancer Recurrent
Trial Timeline
Jul 1, 2014 → Aug 1, 2015
NCT ID
NCT02260544About Doxorubicin Hydrochloride Liposome Injection
Doxorubicin Hydrochloride Liposome Injection is a phase 1 stage product being developed by Dr. Reddy's Laboratories for Ovarian Epithelial Cancer Recurrent. The current trial status is completed. This product is registered under clinical trial identifier NCT02260544. Target conditions include Ovarian Epithelial Cancer Recurrent.
What happened to similar drugs?
11 of 20 similar drugs in Ovarian Epithelial Cancer Recurrent were approved
Approved (11) Terminated (4) Active (7)
Hype Score Breakdown
Clinical
6
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02260544 | Phase 1 | Completed |
Competing Products
20 competing products in Ovarian Epithelial Cancer Recurrent